關(guān)鍵詞： Roche 丙肝藥物 中國
2013年4月18日訊 /生物谷BIOON/ --Roche公司和其合作伙伴Ascletis準(zhǔn)備大力促使其開發(fā)的治療丙肝病毒藥物danoprevir進(jìn)入中國市場,。Roche公司和Ascletis已經(jīng)達(dá)成了一項(xiàng)關(guān)于開拓中國市場的協(xié)議，這項(xiàng)協(xié)議是建立在Roche公司治療丙肝療法--Pegasys銷售額有所降低的背景下,。（生物谷Bioon.com）
詳細(xì)英文報(bào)道：
Roche ($RHHBY) and the biotech startup Ascletis have joined forces to advance Roche's experimental drug danoprevir for hepatitis C virus in the Chinese market. As Reuters reports, the deal comes as Roche sees a decline in sales of its injected interferon therapy Pegasys for hepatitis C, which many researchers want to treat with all-oral drugs. Under the new pact, Ascletis--which launched in 2011 with backing from Chinese real estate mogul Jinxing Qi--is expected to fund development and manufacturing of the drug in China and receive royalties and payments from the Swiss drug giant on potential sales of the protease inhibitor.
(責(zé)任編輯：zengchang)
